Monoclonal Antibody Combo May Lower Viral Loads

A monoclonal antibody drug combo showed promise in lowering viral loads in early-stage COVID-19 outpatients, CIDRAP reports.
Mild- to moderately-ill outpatients given a bamlanivimab and etesevimab combo showed significantly lower viral loads by day 11 than placebo recipients, according to clinical trial results published yesterday in JAMA

The researchers didn’t find a similar effect in those given bamlanivimab alone, but noted that additional study is needed to illuminate the clinical benefits of monoclonal antibodies to treat COVID-19.
Separately, bamlanivimab manufacturer Eli Lilly reported that preventive use of the antibody therapy reduced nursing home residents’ risk of developing symptomatic COVID-19 by as much as 80%, Bloomberg reports. The results of that BLAZE-2 trial of nearly 1,000 residents and staff have not yet been published in a medical journal.
The FDA granted emergency use authorization for bamlanivimab in high-risk outpatients with mild to moderate COVID-19 back in November.

Comments +


Post a Comment

Restricted HTML

  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Back to top